Gilead Emphasizes Unique Ways To Hire Top Talent

When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities. As he perused pharmaceutical companies' job postings, he kept a look out for diversity in leadership, the potential for personal career growth and a commitment to helping improve the lives of people and the health of the world

It was through Gilead's relationship with the National Black MBA Association that he encountered the company. Gilead checked all his boxes, but it was the interview process that really cinched the deal for Jamari. Jasmine Pree Hameth, Senior Director of Corporate Function and Strategic Talent Sourcing at Gilead, connected him with diverse, executive-level Gilead staff so he could learn about their experiences at the company - which, Jamari says, had an impact.

"Before I even started, Jasmine set me up with people within Gilead that I could build networks with and potentially work with," Jamari says. "It didn't feel like they were checking a box hiring me. It was an authentic recruitment process. I thought ‘this is where I need to be, no question about it'."

Today, Jamari works in Sourcing and Procurement at Gilead, where he helps research teams identify and purchase equipment that allows them to create new medications. His experience joining Gilead represents one of several efforts the company is focusing on to hire new, top talent with the belief that diversity drives performance and innovation and helps shape an inclusive culture.

For the past three years, Gilead's Talent Acquisition team has focused on a multi-year set of commitments to increase diversity within the organization's workforce by building relationships with, and by hiring diverse talent from, universities and institutions such as the National Black MBA Association, the National Society of Black Engineers, the National Sales Network and a number of Historically Black Colleges and Universities.

As another part of the recruiting strategy, Gilead also launched a Programming Academy, a four-month program that draws in early and pre-career underrepresented and diverse talent to train them in how to do pharmaceutical programming. This ranges from the curation of data, which means handling data gaps and errors, and analytical programming, which reveals scientific discoveries embedded in data.

Talent Acquisition's efforts are largely focused on building partnerships outside of Gilead's backyard, to ensure that the California-based company finds diverse talent across the United States. Jamari works remotely from Chicago, and the Programming Academy is based in North Carolina.

Gilead's Programming Academy
The Programming Academy is how Adashi Odama discovered Gilead. She graduated with a master's degree in public health last year, and as part of her job hunt attended a Gilead virtual event. It sparked her interest, and when she saw an application online for the academy, she applied. "I always like a new environment, something that's a challenge," she explains. "I'm very interested in data analysis and I do a lot of programming that involves statistics. I thought I could go for it."

Michael Neece, the head of Gilead's Programming Academy, says he created it to fill the gaps in knowledge that he recognized when he started in the pharmaceutical programming world. "We just kind of stumbled into the industry," he says of himself and the two chief instructors. "Hopefully, we're removing some of the barriers to being really successful in the program by having created what we wish we had when we joined."

The Academy offered Adashi a unique opportunity to learn on the job, tackling everything from clinical trials to drug production to Food and Drug Administration rules and regulations. She also learned SAS, a programming software she previously had no experience with.

The training nurtured Adashi's love of statistics and allowed her to focus in on her desire to make a difference. "Once you start to get into statistics, you realize that it tells you pretty much everything," she says. "I think it's a very tangible way to understand health problems, to see exactly what needs to be fixed or what should be addressed."

When Adashi graduated from the Programming Academy last October, she was offered a job with Gilead's inflammation team. "It definitely prepared me for what I'm currently doing," she says of the academy. "I was given the confidence to believe that I could be successful. It laid a very solid foundation, and now I feel I'm able to learn more."

Adashi and Jamari came from different backgrounds, pursued different degrees and lived in different parts of the country. But their commitment to personal growth, and to doing work that makes a difference, is a uniting force that brought them to Gilead.

"Gilead is a company that really values innovation and empowering employees," Jamari says. "You can create a fingerprint at the company quickly. It's been awesome to experience."

Learn more about Gilead Careers.

Originally published by Gilead Sciences

Gilead Sciences, Wednesday, May 10, 2023, Press release picture

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/753946/Gilead-Emphasizes-Unique-Ways-To-Hire-Top-Talent

News Provided by ACCESSWIRE via QuoteMedia

GILD
The Conversation (0)
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

--   If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU --

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex ® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authorisation in July 2020 to provide people living with HDV urgent access to treatment. The CHMP recommendation for full Marketing Authorisation of bulevirtide follows the submission of the Phase 3 MYR301 Week 48 study data, which reinforces the efficacy and safety profile of bulevirtide for the treatment of HDV.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally. Today, some 2.4 million people are living with HCV in the U.S., even though ~95% of those treated with direct-acting antivirals (DAAs) are cured. Prices of HCV medicines have dropped significantly, and many acknowledge that price is not a barrier for most payers and patients. Curative HCV drug therapies are just one part of an elimination strategy that needs to dedicate considerable resources and attention to screening and linkage to care so that all patients in need of HCV treatment can access it in a timely manner and achieve a cure

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion

Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior year

Though the report itself is new, our commitment to practicing ESG is not: We've been guided by Environmental, Social and Governance principles for more than 35 years.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platform

This document corrects and updates the final paragraph in the body of this news release. No other changes were required in this release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Amplia Therapeutics

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report the interim data analysis from the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial). The trial is investigating the combination of the Company’s best-in-class FAK inhibitor narmafotinib with the standard-of-care chemotherapy regimen of gemcitabine and Abraxane®. Data cut-off for the interim analysis is 27 September 2024.

Keep reading...Show less
  InhaleRX

InhaleRx Secures $38,500,000 Funding to Fully Fund Clinical Development Plans

InhaleRx Ltd (ASX: IRX) (‘InhaleRx’ ‘IRX’ or ‘the Company’), an Australian healthcare company developing unique drug-device products to address unmet medical needs in pain management and mental health sectors, is pleased to announce that it has entered into a significant funding agreement with Clendon Biotech Capital Pty Ltd (‘Clendon Biotech Capital’). This strategic partnership will provide the funding to cover all direct costs associated with the Phase 1 & 2 clinical development of the Company's key projects - IRX-211 and IRX-616a.

Keep reading...Show less
  TrivarX

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Keep reading...Show less
Tryptamine Therapeutics Limited

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company is pleased to advise it has received highly encouraging, positive results from its recently completed Phase 2a clinical trial conducted in collaboration with the University of Michigan (‘UOM’) (refer ASX announcement: 10 July 2024). The results are both significant and clinically meaningful, and were presented by UOM researchers at the International Association for the Study of Pain (‘IASP’) 2024 World Congress in the Netherlands on 9 August 2024.

Keep reading...Show less
  LTR Pharma Limited

LTP Secures Global Co-Development Agreement with Aptar Pharma

LTR Pharma Limited (ASX:LTR) (“LTR Pharma”, “the Company”) is pleased to announce that it has entered into a Co-Development Agreement (“the Agreement”) for SPONTAN for global markets.

Keep reading...Show less
CHIMERIC THERAPEUTICS LIMITED

First Patient Enrolled in CHM CDH17 Phase 1/2 Clinical Trial

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the first participant has been enrolled in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

Keep reading...Show less

Latest Press Releases

Related News

×